Article Text

Download PDFPDF
Novel application of infliximab for diversion colitis
  1. Miori Kido1,2,
  2. Ryo Tamura2,
  3. Yoshitomo Yasui2 and
  4. Hideaki Okajima2
  1. 1Department of surgery, Kawasaki Municipal Hospital, Kawasaki, Japan
  2. 2Pediatric Surgery, Kanazawa Medical University, Kahoku-gun, Japan
  1. Correspondence to Mr. Ryo Tamura; nmy.tamura{at}


Diversion colitis (DC) that was refractory to standard treatments was successfully treated with infliximab. A 24-year-old man with a transverse colostomy suffered from severe DC. Topical steroids, 5-aminosalicylic acid (5-ASA) enemas and synbiotics were initially effective, and the colostomy was successfully closed with a covering ileostomy to minimise the risk of anastomotic leakage owing to the damaged colon. DC subsequently relapsed in the entire colon and was refractory to the previous protocol and autologous faecal transplantation. Intravenous methylprednisolone and oral 5-ASA were discontinued owing to possible adverse effects. Infliximab with intravenous prednisolone was introduced, and the protocol was so effective in suppressing the acute colitis that total colectomy was avoided. The stoma was subsequently closed, and the patient is currently symptom-free. Infliximab is used for ulcerative colitis but could also be effective against severe DC.

  • drug therapy related to surgery
  • gastrointestinal system
  • drugs: gastrointestinal system
  • endoscopy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors MK and RT equally contributed to all the works in this article. YY and HO participated in the discussion for this article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.